Palanichamy Ilankumaran
Overview
Explore the profile of Palanichamy Ilankumaran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
578
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Subbiah V, Kreitman R, Wainberg Z, Gazzah A, Lassen U, Stein A, et al.
Nat Med
. 2023 Apr;
29(5):1103-1112.
PMID: 37059834
BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor)...
2.
Kreitman R, Moreau P, Ravandi F, Hutchings M, Gazzah A, Michallet A, et al.
Blood
. 2022 Sep;
141(9):996-1006.
PMID: 36108341
BRAF V600E is the key oncogenic driver mutation in hairy cell leukemia (HCL). We report the efficacy and safety of dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive...
3.
Tan E, Chiparus O, Choudhury S, Kim C, Lau M, Ziltener C, et al.
Clin Pharmacol Drug Dev
. 2022 Jun;
11(10):1203-1210.
PMID: 35736001
Storage of trametinib tablets outside of 2-8°C protected from moisture may lead to loss of dimethyl sulfoxide (DMSO) and adversely impact trametinib bioavailability. In this open-label, phase 1, single-dose, randomized,...
4.
Wen P, Burgess P, Ilankumaran P, Subbiah V
Lancet Oncol
. 2022 Mar;
23(3):e94.
PMID: 35240095
No abstract available.
5.
Arkenau H, Taylor D, Xu X, Chitnis S, Llacer-Perez C, Moore K, et al.
Clin Pharmacol Drug Dev
. 2022 Feb;
11(5):585-596.
PMID: 35157784
This phase 1 postapproval study assessed the effect of the mitogen-activated protein kinase kinase enzyme 1/enzyme 2 inhibitor trametinib (2 mg once daily, repeat dosing) on the pharmacokinetics of combined...
6.
Wen P, Stein A, van den Bent M, De Greve J, Wick A, de Vos F, et al.
Lancet Oncol
. 2021 Nov;
23(1):53-64.
PMID: 34838156
Background: Effective treatments are needed to improve outcomes for high-grade glioma and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated in adult patients with recurrent or...
7.
Subbiah V, Lassen U, Elez E, Italiano A, Curigliano G, Javle M, et al.
Lancet Oncol
. 2020 Aug;
21(9):1234-1243.
PMID: 32818466
Background: Effective treatments for patients with cholangiocarcinoma after progression on gemcitabine-based chemotherapy are urgently needed. Mutations in the BRAF gene have been found in 5% of biliary tract tumours. The...
8.
Si L, Zhang X, Shin S, Fan Y, Lin C, Kim T, et al.
Eur J Cancer
. 2020 Jun;
135:31-38.
PMID: 32534242
Purpose: This study (NCT02083354) assessed the efficacy and safety of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. Method: Overall, 77 patients of East Asian...
9.
Sarafianos S, Clark Jr A, Tuske S, Squire C, Das K, Sheng D, et al.
J Biol Chem
. 2003 Jan;
278(18):16280-8.
PMID: 12554739
A disulfide cross-linking strategy was used to covalently trap as a stable complex (complex N) a short-lived, kinetic intermediate in DNA polymerization. This intermediate corresponds to the product of polymerization...
10.
Sarafianos S, Clark Jr A, Das K, Tuske S, Birktoft J, Ilankumaran P, et al.
EMBO J
. 2002 Nov;
21(23):6614-24.
PMID: 12456667
AZT (3'-azido-3'-deoxythymidine) resistance involves the enhanced excision of AZTMP from the end of the primer strand by HIV-1 reverse transcriptase. This reaction can occur when an AZTMP-terminated primer is bound...